Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100309
N. Tan , C.C. Oh
{"title":"Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review","authors":"N. Tan , C.C. Oh","doi":"10.1016/j.ejcskn.2025.100309","DOIUrl":"10.1016/j.ejcskn.2025.100309","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100309"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100369
A. Wainstein , M. Araújo-Júnior , D. Wainstein
{"title":"Cases report concerning possible relation among the use of Pramipexole Dihydrochloride and the occurrence of melanoma","authors":"A. Wainstein , M. Araújo-Júnior , D. Wainstein","doi":"10.1016/j.ejcskn.2025.100369","DOIUrl":"10.1016/j.ejcskn.2025.100369","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100369"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143747643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100377
M. Hasanov , B. Martin , E. Hasanov , R. Wu , M.S. Goldberg , K.L. Kendra , A. Jarell
{"title":"The 31-GEP identifies patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system","authors":"M. Hasanov , B. Martin , E. Hasanov , R. Wu , M.S. Goldberg , K.L. Kendra , A. Jarell","doi":"10.1016/j.ejcskn.2025.100377","DOIUrl":"10.1016/j.ejcskn.2025.100377","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100377"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100320
E. Samaniego González , M. Criado Otero , M. Navedo de las Heras , P. Bodas Gallego
{"title":"Patient with Gorlin Syndrome and type 2 mosaicism successfully treated with sonidegib","authors":"E. Samaniego González , M. Criado Otero , M. Navedo de las Heras , P. Bodas Gallego","doi":"10.1016/j.ejcskn.2025.100320","DOIUrl":"10.1016/j.ejcskn.2025.100320","url":null,"abstract":"","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100320"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143748338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100728
Lisanne P. Zijlker , Francesca Watts , Terence Wong , Claudie C. Flohil , Serigne N. Lo , Ines P. da Silva , Sydney Ch’ng , Angela M. Hong , Kerwin F. Shannon , W. Martin C. Klop , Winan J. van Houdt , Michel W.J.M. Wouters , Margot Tesselaar , Richard A. Scolyer , Alexander C.J. van Akkooi
Background
A sentinel lymph node biopsy (SLNB) provides important prognostic information in patients with Merkel cell carcinoma (MCC). However, there are no histopathological prognostic factors known to identify high-risk patients amongst those with a positive sentinel lymph node (SLN). In this study we aim to assess the prognostic value of SLN tumor burden and the histological pattern of spread in SLN positive MCC.
Methods
The pathology specimen of all patients with MCC who underwent SLNB procedure between 2005 and 2022 was reviewed. SLN tumor burden was measured as the largest diameter of the tumor deposit. Additionally, 5 different histological patterns of sentinel node involvement were scored.
Results
There were 131 patients included of whom 46 had a positive SLN. At two years, the overall survival (OS) was significantly higher in patients with a lower than median SLN tumor burden (<0.625 mm) as compared to those with a high SLN tumor burden (90 % vs. 63 %, p = 0.046). There was a non-significant difference in 2-year recurrence-free survival (61 % vs. 37 %, p = 0.082) and disease-specific survival (100 % and 85 %, p = 0.078). A trend towards better OS was observed for patients with a non-solid compared to a solid histological pattern of sentinel lymph node involvement (84 % vs. 60 %, p = 0.061). In a multivariable analysis both immunosuppression (HR 3.9, p = 0.009) and extracapsular extension (HR 8.8, p = 0.002) were significant prognostic factors for OS.
Conclusion
MCC patients with a lower SLN tumor burden had a significantly better 2-year OS.
前哨淋巴结活检（SLNB）为默克尔细胞癌（MCC）患者提供了重要的预后信息。然而，目前还没有已知的组织病理学预后因素来识别前哨淋巴结（SLN）阳性的高危患者。在本研究中，我们旨在评估SLN肿瘤负荷的预后价值和SLN阳性MCC的组织学扩散模式。方法回顾性分析2005 ~ 2022年间行SLNB手术的所有MCC患者的病理标本。SLN肿瘤负荷以肿瘤沉积物的最大直径测量。此外，对前哨淋巴结受累的5种不同组织学模式进行评分。结果131例患者中46例SLN阳性。两年时，SLN肿瘤负荷低于中位数（<0.625 mm）的患者的总生存率（OS）明显高于SLN肿瘤负荷较高的患者（90 %对63 %，p = 0.046）。2年无复发生存率（61 % vs. 37 %,p = 0.082）和疾病特异性生存率（100 %和85 %，p = 0.078）差异无统计学意义。与前哨淋巴结累及的实性组织学模式相比，观察到非实性的患者有更好的OS趋势（84 %对60 %，p = 0.061）。在多变量分析中，免疫抑制（HR 3.9, p = 0.009）和囊外延伸（HR 8.8, p = 0.002）是OS的重要预后因素。结论低SLN肿瘤负荷的mcc患者具有较好的2年OS。
{"title":"Prognostic significance of sentinel node tumor burden in Merkel Cell Carcinoma","authors":"Lisanne P. Zijlker , Francesca Watts , Terence Wong , Claudie C. Flohil , Serigne N. Lo , Ines P. da Silva , Sydney Ch’ng , Angela M. Hong , Kerwin F. Shannon , W. Martin C. Klop , Winan J. van Houdt , Michel W.J.M. Wouters , Margot Tesselaar , Richard A. Scolyer , Alexander C.J. van Akkooi","doi":"10.1016/j.ejcskn.2025.100728","DOIUrl":"10.1016/j.ejcskn.2025.100728","url":null,"abstract":"<div><h3>Background</h3><div>A sentinel lymph node biopsy (SLNB) provides important prognostic information in patients with Merkel cell carcinoma (MCC). However, there are no histopathological prognostic factors known to identify high-risk patients amongst those with a positive sentinel lymph node (SLN). In this study we aim to assess the prognostic value of SLN tumor burden and the histological pattern of spread in SLN positive MCC.</div></div><div><h3>Methods</h3><div>The pathology specimen of all patients with MCC who underwent SLNB procedure between 2005 and 2022 was reviewed. SLN tumor burden was measured as the largest diameter of the tumor deposit. Additionally, 5 different histological patterns of sentinel node involvement were scored.</div></div><div><h3>Results</h3><div>There were 131 patients included of whom 46 had a positive SLN. At two years, the overall survival (OS) was significantly higher in patients with a lower than median SLN tumor burden (<0.625 mm) as compared to those with a high SLN tumor burden (90 % vs. 63 %, p = 0.046). There was a non-significant difference in 2-year recurrence-free survival (61 % vs. 37 %, p = 0.082) and disease-specific survival (100 % and 85 %, p = 0.078). A trend towards better OS was observed for patients with a non-solid compared to a solid histological pattern of sentinel lymph node involvement (84 % vs. 60 %, p = 0.061). In a multivariable analysis both immunosuppression (HR 3.9, p = 0.009) and extracapsular extension (HR 8.8, p = 0.002) were significant prognostic factors for OS.</div></div><div><h3>Conclusion</h3><div>MCC patients with a lower SLN tumor burden had a significantly better 2-year OS.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100728"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143737918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100757
Apurva Shirodkar , Sandy Salama , Aliya Pardhan , the Melanoma Delphi Panel and International Melanoma Expert Panel, Susan Blacker , Cholly Boland , Marcus O. Butler , Darren C. Cargill , An-Wen Chan , Annette Cyr , Mark B. Faries , Leta Forbes , Tim Hanna , Renee Hanrahan , Brian Hasegawa , Kevin Higgins , Anthony M. Joshua , Wade Mitchell , Marc Moncrieff , Rachael L. Morton , Frances C. Wright
Purpose
To identify consensus-based quality indicators to evaluate melanoma care.
Methods
Melanoma quality indicators were identified from a literature review. Twenty-nine indicators in six topic domains were subsequently developed: diagnosis and diagnostic biopsy, patient experience, treatment, pathology, symptom management, survivorship. Clinical experts in melanoma from Ontario and international jurisdictions, representing the disciplines of surgery, pathology, primary care, medical oncology, radiation oncology, and palliative care, in addition to a health system leader, an epidemiologist and a patient and family advisor were invited to participate on the Delphi Panel. Panelists were asked to rate indicators on a nine-point Likert scale for appropriateness. Two iterations of electronic surveys were anonymously completed, followed by a virtual consensus meeting to prioritize quality and outcome melanoma indicators.
Results
Twenty-three panel members participated in the modified-Delphi process. Twenty-three quality indicators reflecting high-quality melanoma care across the care continuum were prioritized based on a defined consensus agreement of ≥ 80 % although only 4 were measurable from current administrative databases. These indicators were assessed for measurement feasibility and four of these were deemed feasible to measure from administrative databases along with eight standard indicators.
Conclusion
Melanoma outcome and quality indicators were identified using a modified-Delphi process for inclusion in a provincial cancer system performance report.
{"title":"Defining melanoma quality indicators: A modified Delphi approach","authors":"Apurva Shirodkar , Sandy Salama , Aliya Pardhan , the Melanoma Delphi Panel and International Melanoma Expert Panel, Susan Blacker , Cholly Boland , Marcus O. Butler , Darren C. Cargill , An-Wen Chan , Annette Cyr , Mark B. Faries , Leta Forbes , Tim Hanna , Renee Hanrahan , Brian Hasegawa , Kevin Higgins , Anthony M. Joshua , Wade Mitchell , Marc Moncrieff , Rachael L. Morton , Frances C. Wright","doi":"10.1016/j.ejcskn.2025.100757","DOIUrl":"10.1016/j.ejcskn.2025.100757","url":null,"abstract":"<div><h3>Purpose</h3><div>To identify consensus-based quality indicators to evaluate melanoma care.</div></div><div><h3>Methods</h3><div>Melanoma quality indicators were identified from a literature review. Twenty-nine indicators in six topic domains were subsequently developed: diagnosis and diagnostic biopsy, patient experience, treatment, pathology, symptom management, survivorship. Clinical experts in melanoma from Ontario and international jurisdictions, representing the disciplines of surgery, pathology, primary care, medical oncology, radiation oncology, and palliative care, in addition to a health system leader, an epidemiologist and a patient and family advisor were invited to participate on the Delphi Panel. Panelists were asked to rate indicators on a nine-point Likert scale for appropriateness. Two iterations of electronic surveys were anonymously completed, followed by a virtual consensus meeting to prioritize quality and outcome melanoma indicators.</div></div><div><h3>Results</h3><div>Twenty-three panel members participated in the modified-Delphi process. Twenty-three quality indicators reflecting high-quality melanoma care across the care continuum were prioritized based on a defined consensus agreement of ≥ 80 % although only 4 were measurable from current administrative databases. These indicators were assessed for measurement feasibility and four of these were deemed feasible to measure from administrative databases along with eight standard indicators.</div></div><div><h3>Conclusion</h3><div>Melanoma outcome and quality indicators were identified using a modified-Delphi process for inclusion in a provincial cancer system performance report.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100757"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145264445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-01DOI: 10.1016/j.ejcskn.2025.100741
Enrica Teresa Tanda , Michela De Mattia , Alessia Graziana Bosio , Giovanni Rossi , Andrea Boutros , Agostina Lagodin d’Amato , Claudia Massarotti , Francesco Spagnolo , Mario Mandalà
The relationship between melanoma and female hormonal factors has long been a subject of investigation. While pregnancy-associated melanoma (PAM) has been widely studied, current evidence does not consistently demonstrate an increased risk of developing melanoma during pregnancy or a worse prognosis in pregnant women with pre-existing disease. This narrative review expands the scope beyond PAM, focusing specifically on the potential impact of hormone replacement therapy (HRT) and fertility treatments on melanoma risk and progression. We performed a comprehensive review of the literature, analyzing studies that explored the association between exogenous hormonal exposure and melanoma development, recurrence, or progression. Available evidence is often conflicting and limited by methodological heterogeneity. Some studies suggest a possible increased risk of melanoma with prolonged use of certain hormonal agents, particularly oral contraceptives and fertility drugs, while others do not support a significant association. The influence of these treatments on prognosis remains unclear. Our goal is to provide clinicians with a critical synthesis of existing data and practical insights for managing younger female patients with melanoma or at risk of melanoma. This review underscores the importance of individualized risk assessment and shared decision-making when hormonal therapies are considered in this setting. Further prospective studies are needed to clarify these associations and inform evidence-based clinical guidelines.
{"title":"Melanoma-specific risk associated with hormone replacement therapy and fertility treatments: A narrative review and a clinical guide","authors":"Enrica Teresa Tanda , Michela De Mattia , Alessia Graziana Bosio , Giovanni Rossi , Andrea Boutros , Agostina Lagodin d’Amato , Claudia Massarotti , Francesco Spagnolo , Mario Mandalà","doi":"10.1016/j.ejcskn.2025.100741","DOIUrl":"10.1016/j.ejcskn.2025.100741","url":null,"abstract":"<div><div>The relationship between melanoma and female hormonal factors has long been a subject of investigation. While pregnancy-associated melanoma (PAM) has been widely studied, current evidence does not consistently demonstrate an increased risk of developing melanoma during pregnancy or a worse prognosis in pregnant women with pre-existing disease. This narrative review expands the scope beyond PAM, focusing specifically on the potential impact of hormone replacement therapy (HRT) and fertility treatments on melanoma risk and progression. We performed a comprehensive review of the literature, analyzing studies that explored the association between exogenous hormonal exposure and melanoma development, recurrence, or progression. Available evidence is often conflicting and limited by methodological heterogeneity. Some studies suggest a possible increased risk of melanoma with prolonged use of certain hormonal agents, particularly oral contraceptives and fertility drugs, while others do not support a significant association. The influence of these treatments on prognosis remains unclear. Our goal is to provide clinicians with a critical synthesis of existing data and practical insights for managing younger female patients with melanoma or at risk of melanoma. This review underscores the importance of individualized risk assessment and shared decision-making when hormonal therapies are considered in this setting. Further prospective studies are needed to clarify these associations and inform evidence-based clinical guidelines.</div></div>","PeriodicalId":100396,"journal":{"name":"EJC Skin Cancer","volume":"3 ","pages":"Article 100741"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145026761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号